Halaven (eribulin mesylate)

eribulin mesylate · Eisai Co., Ltd.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for Halaven (eribulin mesylate), covering 2012-08-29 to 2026-03-18. Get the full timeline:

Most recent: Clinical Trial Update: Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC